Article
Pharmacology & Pharmacy
Yeon Jeong Kim, Fen Jiang, Jin Park, Hyeon Hee Jeong, Ji Eun Baek, Seung-Mo Hong, Seong-Yun Jeong, Sang Seok Koh
Summary: The study reveals the tumor-promoting role of PAUF in ovarian cancer and suggests that an anti-PAUF antibody may have therapeutic effects on high PAUF-expressing ovarian cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
O. Ngozi Nwaefulu, S. Rao Sagineedu, M. Kaisarul Islam, J. Stanslas
Summary: Pancreatic cancer is a difficult-to-treat disease with a high fatality rate. End-stage pancreatic cancer currently has no specific treatment, but surgery, radiation, and chemotherapy can extend patients' survival. This article summarizes various targeted therapies for pancreatic cancer, including the use of inhibitors and monoclonal antibodies.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Article
Oncology
Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu Tojo
Summary: The study found that the combination of HDAC inhibitor and Akt inhibitor holds promise for the treatment of relapsed/refractory MM, as HDAC inhibitors suppressed drug-resistant MM cell growth and enhanced antibody-dependent cellular cytotoxicity, while also downregulating c-Myc through GSK-3 phosphorylation blockage.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Cell Biology
Ming He, Wenxing Lv, Yu Rao
Summary: PROTAC is a new technology for inducing protein degradation using small molecules, which shows advantages in overcoming tumor resistance, affecting non-enzymatic functions of target proteins, degrading undruggable targets, and providing rapid and reversible chemical knockout tools. However, it also faces challenges and issues as a rapidly developing new chemical biology technology.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Xiu-Fang Li, Chen-Fu Liu, Guo-Wu Rao
Summary: The human epidermal growth factor receptor family, including HER1/EGFR/ErbB1, HER2/NEU/ErbB2, HER3/ErbB3 and HER4/ErbB4, belongs to transmembrane receptor tyrosine kinases (RTKs) and participates in signal transduction and oncogenesis. These receptors have similar structures, with extracellular and intracellular domains serving different functions.
CURRENT MEDICINAL CHEMISTRY
(2021)
Review
Pharmacology & Pharmacy
Maryam M. J. Fallatah, Fiona Law, Warren A. Chow, Peter Kaiser
Summary: The tumor suppressor p53 is frequently mutated in human cancer and is a high-value target for precision oncology. p53 prevents cancer by inducing cell-cycle arrest and cell death. Tumors have evolved mechanisms to inactivate p53, mainly through TP53 mutations or hyperactive degradation. This review focuses on MDM2 antagonists and mutant p53 correctors as p53-targeting compounds, discussing their mode of action and the challenges in advancing them to the clinic.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2023)
Article
Multidisciplinary Sciences
Lisa Hiepp, Doris Mayr, Kathrin Gaertner, Elisa Schmoeckel, Frederick Klauschen, Alexander Burges, Sven Mahner, Reinhard Zeidler, Bastian Czogalla
Summary: Targeting the tumor-associated carbonic anhydrase XII (CA XII) is considered a promising strategy to improve cancer treatment. This study provides deeper information about the expression profile of CA XII in ovarian carcinomas, revealing significant expression in most tumor samples and ascites-derived cells. Higher levels of CA XII were found in ovarian carcinomas compared to borderline tumors and non-neoplastic ovarian epithelia. High expression of CA XII was associated with higher tumor grading and a trend towards shorter overall survival. The results suggest that CA XII plays a crucial role in the malignancy of ovarian carcinoma cells and has potential as a diagnostic marker and therapeutic target.
Article
Chemistry, Multidisciplinary
Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, Toru Tanaka, Yuquan Tong, Raphael I. Benhamou, Jared Baisden, Gogce Crynen, Samantha M. Meyer, Michael D. Cameron, Arnab K. Chatterjee, Alexander Adibekian, Jessica L. Childs-Disney, Matthew D. Disney
Summary: By reprogramming Dovitinib to target pre-miR-21, researchers successfully improved selectivity across different biomolecules and alleviated disease progression in mouse models of breast cancer and Alport Syndrome.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2021)
Review
Pharmacology & Pharmacy
Xu Huang, Xiao-Yu Li, Wu-Lin Shan, Yao Chen, Qi Zhu, Bai-Rong Xia
Summary: Currently, ovarian cancer has the highest mortality rate among all gynecological cancers. The standard treatment protocol involves initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy. However, traditional chemotherapy has limited efficacy due to drug resistance and recurrence. With the advent of precision medicine, molecular targeted therapy has emerged as a promising approach for ovarian cancer treatment. Genetic mutations, such as BRCA and HRD gene mutations, can guide targeted drug treatment and improve patient prognosis. This article reviews different targeted therapy sites and pathways, along with the latest research progress in preclinical and clinical trials related to ovarian cancer therapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Nicolas Lepareur, Barthelemy Ramee, Marie Mougin-Degraef, Mickael Bourgeois
Summary: Targeted radionuclide therapy has become prominent in nuclear medicine, aiming to achieve high selectivity at the tumor level while limiting dosage to healthy tissues. Advancements in cancer molecular mechanisms, innovative targeting agents, and new radioisotopes have allowed for better therapeutic efficacy, radiation safety, and personalized treatments. Several radiopharmaceuticals for therapeutic targeting have shown clinical value and will be approved for clinical use.
Article
Biotechnology & Applied Microbiology
Jinyu Wang, Yikang He, Baoyue Wang, Ruian Yin, Biao Chen, Hongxing Wang
Summary: This study introduces a new strategy for treating sarcopenia by using targeted nanoparticle AP@SW033291, which can improve the treatment efficacy.
Review
Cell Biology
Guoqiang Sun, Dawei Rong, Zhouxiao Li, Guangshun Sun, Fan Wu, Xiao Li, Hongyong Cao, Ye Cheng, Weiwei Tang, Yangbai Sun
Summary: Research on molecular targeted therapy of tumors is thriving, with novel targeted therapy drugs constantly emerging. Small molecule targeted compounds can be administered orally, do not elicit immune response, and are cost-effective, making them a hot topic in tumor treatment research.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Victor Albarran, Diana Isabel Rosero, Jesus Chamorro, Javier Pozas, Maria San Roman, Ana Maria Barrill, Victor Alia, Pilar Sotoca, Patricia Guerrero, Juan Carlos Calvo, Inmaculada Orejana, Patricia Perez de Aguado, Pablo Gajate
Summary: Metastatic urothelial cancer is a major cause of cancer-related death, but new treatment approaches targeting Her-2 show promise, especially with the emergence of antibody-drug conjugates as a novel therapy for advanced cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Arnon Moldrup Knudsen, Henning Bunsow Boldt, Elisabeth Victoria Jakobsen, Bjarne Winther Kristensen
Summary: The multi-target small-molecule inhibitor SB747651A showed anticancer effects in glioblastoma by reducing cell proliferation, migration, and chemoresistance, inducing apoptotic cell death, and prolonging survival in mice with intracranial glioblastoma xenografts. Further research is needed to clarify its mechanisms of action before potential clinical application as an anticancer agent.
SCIENTIFIC REPORTS
(2021)
Review
Cell Biology
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson
Summary: This review critically analyzes the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.